Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European acute promyelocytic leukemia group

Journal of Clinical Oncology

Volumn 24, Issue 36, 2006, Pages 5703-5710

  Adès, Lionel ^a   Chevret, Sylvie ^a   Raffoux, Emmanuel ^a   De Botton, Stephane ^a   Guerci, Agnes ^a   Pigneux, Arnaud ^a   Stoppa, Anne Marie ^a   Lamy, Thierry ^a   Rigal Huguet, Francoise ^a   Vekhoff, Anne ^a   Meyer Monard, Sandrine ^a   Maloisel, Frederic ^a   Deconinck, Eric ^a   Ferrant, Augustin ^a   Thomas, Xavier ^a   Fegueux, Nathalie ^a   Chomienne, Christine ^a   Dombret, Herve ^a   Degos, Laurent ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TREATMENT OUTCOME; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRETINOIN;

EID: 34247369329     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.1596     Document Type: Article

References (49)

1. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
2. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543-553, 1992
3. Larson RA, Kondo K, Vardiman JW, et al: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76: 827-841, 1984
4. de The H, Lavau C, Marchio A, et al: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684, 1991
5. Kakizuka A, Miller WH Jr, Umesono K, et al: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674, 1991
6. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215, 1999
7. Cunningham I, Gee TS, Reich LM, et al: Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 73:1116-1122, 1989
8. Fenaux P, Pollet J, Vandenbossche L, et al: Treatment of acute promyelocytic leukemia: A report on 70 cases. Leuk Lymphoma 4:249, 1991
9. Head D, Kopecky KJ, Weick J, et al: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717-1728, 1995
10. Head DR, Kopecky KJ, Willman C, et al: Treatment outcome with chemotherapy in acute promyelocytic leukemia: The Southwest Oncology Group (SWOG) experience. Leukemia 8:S38-S41, 1994 (suppl 2)
11. Avvisati G, Petti MC, Lo Coco F, et al: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 100:3141-3146, 2002
12. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
13. Chomienne C, Ballerini P, Balitrand N, et al: All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure-function relationship. Blood 76:1710-1717, 1990
14. Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709, 1990
15. Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393, 1991
16. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial - European APL 91 Group. Blood 82:3241-3249, 1993
17. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
18. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 94:1192-1200, 1999
19. Ades L, Chevret S, De Botton S, et al: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: The European group experience. Leukemia 19:230-233, 2005
20. Estey E, Thall PF, Pierce S, et al: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483-490, 1997
21. Sanz MA, Martin G, Gonzalez M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 103:1237-1243, 2004
22. Sanz MA, Lo Coco F, Martin G, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000
23. Sanz MA, Martin G, Rayon C, et al: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia: PETHEMA group. Blood 94:3015-3021, 1999
24. Frankel SR, Eardley A, Heller G, et al: All-trans retinoic acid for acute promyelocytic leukemia: Results of the New York Study. Ann Intern Med 120:278-286, 1994
25. De Botton S, Dombret H, Sanz M, et al: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 92:2712-2718, 1998
26. Bolufer P, Lo Coco F, Grimwade D, et al: Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica 86:570-576, 2001
27. Sanz MA, Tallman MS, Lo-Coco F: Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105:3019-3025, 2005
28. Cassinat B, Zassadowski F, Balitrand N, et al: Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14:324-328, 2000
29. Lo Coco F, Avvisati G, Diverio D, et al: Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 77:1657-1659, 1991
30. Cheson B, Cassileth P, Head D, et al: Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
31. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
32. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
33. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
34. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1998
35. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
36. Sanz MA, Vellenga E, Rayon C, et al: All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 104:3490-3493, 2004
37. Creutzig U, Ritter J, Zimmermann M, et al: Idarubicin improves blast cell clearance during induction therapy in children AML: Results of study AML-BFM 93 - AML-BFM study group. Leukemia 15:348-354, 2001
38. Wiernik P, Banks P, Case D, et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992
39. Volger W, Velez-Garcia E, Weiner R, et al: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111, 1992
40. Casazza AM, Pratesi G, Giuliani F, et al: Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66:549-564, 1980
41. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301, 2004
42. Lengfelder E, Reichert A, Schoch C, et al: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia - German AML Cooperative Group. Leukemia 14:1362-1370, 2000
43. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101: 5328-5335, 2004
44. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
45. Raffoux E, Rousselot P, Poupon J, et al: Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334, 2003
46. Estey E, Garcia-Manero G, Ferrajoli A, et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469-3473, 2006
47. Mathews V, George B, Lakshmi K, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107: 2627-2632, 2006
48. Gavamzadeh A, Alimoghaddam K, Ghaffari S, et al: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 17:131-134, 2006
49. de Botton S, Sanz M, Chevret S, et al: Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20:35-41, 2006